Evidence map›Paper›PMID 40456843›Full record

ArticleScientific reports2025

Design and evaluation of substituted cinnamoyl piperidinyl acetate derivatives as potent cholinesterase inhibitors.

Maryam Esmkhani, Shahrzad Javanshir, Aida Iraji, Mohammad Mahdavi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maryam EsmkhaniPharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846-13114, Iran.
Shahrzad JavanshirPharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846-13114, Iran. shjavan@iust.ac.ir.
Aida IrajiResearch Center for Traditional Medicine and History of Medicine, Department of Persian Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. iraji@sums.ac.ir.
Mohammad MahdaviEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Funding

Vice-Chancellor for Research, Shiraz University of Medical Sciences IR.SUMS.REC.1404.046
6 · The paper itself

Abstract

In the pursuit of therapeutic agents for Alzheimer's disease (AD), this study employed a molecular hybridization strategy to design and synthesize substituted cinnamoyl piperidinyl acetates. A total of 17 novel derivatives were evaluated for their inhibitory effects against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), key enzymes implicated in AD pathogenesis. Notably, compound 5b, featuring a 2-chloro substitution, emerged as the most potent AChE inhibitor (IC

Indexed as

AcetatesCholinesterase InhibitorsDrug DesignPiperidinesAcetylcholinesteraseAlzheimer DiseaseButyrylcholinesteraseHumansKineticsMolecular Docking SimulationStructure-Activity RelationshipAcetatesAcetylcholinesteraseButyrylcholinesteraseCholinesterase InhibitorsPiperidinesAcetylcholinesterase inhibitorsButyrylcholinesterase inhibitorCinnamoylDrug-LikenessMolecular dynamicsPiperidinyl

Identifiers

PMID40456843
PMCPMC12130451

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.